
Federal government commits to fixing Australian healthcare system to better help women
As part of women's health week on 7NEWS, dozens of women have come forward revealing misdiagnoses that could have cost them their lives.
Know the news with the 7NEWS app: Download today
With endometriosis, a condition causing severe pelvic pain, affecting one in seven women, Butler promised to make it a 'national priority.'
'What we're trying to do is increase the capabilities of GPs, the front-line service for most Australian women to diagnose quickly and to give good support to Australian women with this condition,' he told 7NEWS health editor Jennifer Bechwati.
'We're also opening specialist endometriosis and pelvic pain clinics for women who have particularly severe and complex symptoms to provide specialist support and lastly, the really critical thing is to make sure that women have access to the best available medicines.'
Maternity closures
The federal government has promised to increase capabilities in public hospitals, where private hospital maternity wards have shut down across the country.
But the sector warns it's not enough, foreshadowing more closures this year.
Butler says health insurers need to look at changing policy benefits to give women more access to the care they deserve.
'We've said to the insurers that we think they need to consider providing maternity beyond just gold products for private health insurance.'
'A lot of families are buying silver or even bronze products, we think they should consider expanding access to maternity cover beyond just gold product.'
Cancer
Increased awareness, research and development of treatments for specific cancers have seen survival rates soar over the past two decades. But many are still falling behind.
Ovarian cancer, which kills one Australian woman every eight hours, receives only a fraction of funding compared with other cancers, including prostate.
Asked whether he will commit to closing that funding gap, the health minister replied: 'We want to see that gap closed, whether it's in access to medicines or the sort of nurse and navigation support that patients and their families need while they're going through the cancer journey.'
Mental health
As 7NEWS revealed this week, one in two Australian women will be impacted by a mental health issue at some point in their life, with millions now seeking help online.
Two thirds of online inquires at SANE, one of Australia's leading mental health groups, are now women.
But services targeted at those over the age of 40, who carry significant burden, are in dire need of funding.
The federal government has promised to increase free options for women seeking support.
'We don't want affordability to be a barrier to people getting the mental health support that they need, that's why we're opening more Medicare mental health centres,' Butler said.
But he conceded staff shortages could hamper those efforts.
'One of the real constraints is we don't have enough psychologists, we don't have enough psychiatrists to provide the support that our community needs right now,' he said.
'During the election campaign we promised to build on the work we did last term in expanding the psychology workforce in particular to make sure that people have that opportunity to go and get support that they need.'
Menopause
Butler welcomed what he says is a 'growing conversation' on issues associated with menopause and peri menopause, promising to continue making medicines cheaper and supporting GPs to help women through this major transition in life.
He said he was 'shocked' to hear that some medical degrees of fix or six years contain only one hour's training on menopause, a condition that impacts half of the patients doctors will see.
'We're increasing the capability of GPs to support women through this phase of their life,' Butler said.
'We're listing new medicines (on the Pharmaceutical Benefits Scheme). It had been more than 20 years since there had been a new hormone treatment for women going through menopause on the PBS.'
Misogyny
Asked how the government plans to fix medical misogyny so women no longer feel dismissed, Butler conceded: 'We know there's much, much more to do.'
'(We need) to provide women with more choice, with better access and lower cost. They have a range of issues associated with simply being a woman that haven't got the proper attention in the Australian healthcare system.
'But I think what we've done over the last couple of years to improve choice, to improve access and to improve affordability is making a meaningful difference.'
Butler has been re-appointed health and aged care minister, and will take on the new portfolio of NDIS in the re-elected Albanese government.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sky News AU
18 minutes ago
- Sky News AU
Esteemed ABC journalist and Walkley Award winner Peter Ryan tragically dies aged 64 after long fight with thyroid cancer
Walkley Award-winning journalist and long-time ABC correspondent Peter Ryan has died at the age of 64, following a long battle with metastatic thyroid cancer. The beloved broadcaster passed away in Sydney on Friday night, just weeks after retiring from the ABC and entering palliative care. He had worked with the national broadcaster for 45 years. Ryan was first diagnosed with the disease in 2014, but continued to build a remarkable career at the national broadcaster before stepping back in June to spend time with his wife, Mary Cotter, and daughter, Charlotte. He served as the ABC's senior business correspondent from 2016, a role in which he became a trusted voice on economic affairs. His journalism career began straight out of school at the age of 18, when he landed a job in 1980 as a copyboy and cadet at Sydney's Daily Mirror. But it was at the ABC, which he called his "spiritual home", where he truly made his mark, contributing to flagship radio programs including AM, The World Today, and PM. His 2017 investigation into the Commonwealth Bank scandal, which revealed how deposit machines were being exploited by drug syndicates to launder millions, earned him a prestigious Walkley Award. In 2022, he was appointed a Member of the Order of Australia for his services to journalism. The ABC paid tribute to Ryan on Saturday, remembering him as a dedicated and much-loved figure in the newsroom. "The ABC is deeply saddened by the death of our great friend and esteemed colleague Peter Ryan," the broadcaster said in a statement. "After a distinguished 45-year career in journalism Peter retired from the ABC last month due to ill health. We extend our heartfelt condolences to Peter's family." ABC News Director Justin Stevens described Ryan's impact on Australian journalism as "profound". "Through his mentorship, friendship, and professionalism, he directly touched the lives of many at the ABC," Stevens said. "Through his journalism, he had a profound impact on the lives of Australians and our society. It was a privilege to know him and work alongside him." Former ABC News Breakfast host Michael Rowland also paid tribute on LinkedIn, describing Ryan as "a distinguished ABC Washington bureau chief and, later, one of Australia's pre-eminent business journalists." "If you wanted to know what was going on in corporate Australia, Peter was your man. His contacts and record of story-breaking were unrivalled," Rowland said. He praised Ryan's "courageous journalism" as well as his generosity as a mentor and leader, saying: "He had a big impact on so many ABC careers, including mine. "When I last saw him in hospital a few weeks ago, Peter was full of old stories and good cheer, despite his health challenges. "We've all lost a good one." Federal Treasurer Jim Chalmers also honoured Ryan at the time of his retirement, calling him "an absolute legend". "Every day as you wake up and you think about what's happening in the economy, if you only needed to listen to one voice to be sure that you got its essential elements, it would be Peter's," Chalmers said. In a final message shared with ABC staff upon his retirement, Ryan left a note with advice for "younger and older colleagues alike". Among his parting words were: "Be kind and caring to people who need it." Peter Ryan is survived by his wife Mary and daughter Charlotte.

9 News
2 hours ago
- 9 News
Doctors call for use of spinal cord stimulators to be reconsidered
Your web browser is no longer supported. To improve your experience update it here Australian doctors and health fund providers are calling for the use of spinal cord stimulators to be reconsidered after research revealed one-in-four people are having revision surgery for complications. Spinal cord stimulators have been used to treat chronic pain, including back pain, neck pain, nerve pain, and complex regional pain syndrome. The devices are made up of a small battery pack, which is implanted beneath the skin and attached to electrodes. Pulses of electricity are theoretically supposed to interfere with pain signals coming from the nerves. An image showing what a spinal cord stimulator would look like when inserted into a patient. (iStock) However, a study by leading Australian doctors, published in this week's Medical Journal of Australia , found 23 per cent of patients fitted with the device will go on to need revision surgery for complications within three years. The median cost for the permanent device is nearly $56,000, with some patients' treatment adding up to more than $500,000. "Given the lack of supportive data for their efficacy, and a concerning harms profile, use of spinal cord stimulators for pain control should be reconsidered," the researchers wrote in the journal. Lead author Dr Caitlin Jones, from the University of Sydney's Institute of Musculoskeletal Health, told The Sydney Morning Herald the risk posed by the devices was much greater than the likely benefits. "Patients should know they are taking on a substantial risk, that is exorbitantly expensive, with very little likelihood of any benefit." Private Healthcare Australia, which represents health insurance funds and their 15 million members, has backed the researchers' calls for the use of the devices to be reconsidered. PHA CEO Dr Rachel David said while the Therapeutic Goods Administration (TGA) last year cancelled the registration of some spinal cord stimulators and imposed conditions on others, they were still available and being used on patients. "The regulatory action taken so far has been insufficient. Put simply, if these spinal cord stimulators were new technologies trying to get listed for Medicare funding in Australia, they would be deemed too dangerous," she said. "The Australian Government should ask the Medicare Services Advisory Committee to assess these devices and consider if they meet contemporary standards for listing. If not, the Medicare items and devices should be removed. This would protect patients from unnecessary harm and reduce wasteful expenditure for taxpayers and people with health insurance who are effectively being forced to fund this." At least 90 per cent of spinal cord stimulators are inserted in the private health sector. "Health funds are committed to continuing to fund evidence-based treatments which have demonstrated safety and efficacy in the treatment of chronic pain," David said. The Medical Technology Association of Australia (MTAA), which represents device manufacturers has said the devices are safe and effective. Stimulators were "a demonstrably safe and effective alternative to long-term drug therapies, notably opioids", a spokesman told The Sydney Morning Herald. "[Stimulator] suppliers stand behind the safety, quality and efficacy of our SCS technologies that have demonstrated positive outcomes for patients, which are backed by robust clinical trial data and real-world evidence." health Health Services national Australia Research CONTACT US

News.com.au
3 hours ago
- News.com.au
Hot Money Monday: Proteomics brings science to racehorse recovery, as animal health booms
New blood test reveals hidden muscle damage in racehorses Proteomics' OxiDx helps trainers spot injuries early and avoid breakdowns ASX-listed stocks with exposure to the animal sector. In the high-octane world of thoroughbred racing, muscle is money. Every gallop, every second shaved off the clock comes down to conditioning, training, and recovery. But what happens when something breaks, and you don't even know it? That's the riddle Proteomics International Laboratories (ASX:PIQ) and its subsidiary OxiDx are solving with a groundbreaking new test that can detect muscle damage in racehorses. Last Monday, Proteomics announced a major update. Its patented OxiDx test has now proven – via peer-reviewed research – that it can track oxidative stress and pinpoint muscle injury in thoroughbred racehorses post-race. In short: trainers and vets now have hard data instead of relying on gut feel. Published in Veterinary Medicine and Science, the study tracked 34 Australian racehorses across seven days after racing. Using a dried blood spot from each horse, the OxiDx test measured thiol-oxidised albumin, a protein biomarker of oxidative stress. The findings were clear: oxidative stress levels peaked two days after a race and stayed elevated for up to five. Some horses took even longer to recover. That variability suggests that one horse might bounce back after 48 hours, while another might still be nursing invisible damage a week later. And if you're a trainer pushing too hard, too soon, that kind of hidden strain can lead to breakdowns. In fact, up to 85% of thoroughbreds suffer at least one injury during their early racing years, many of them muscle-related and many going undiagnosed until it's too late. OxiDx redefines racehorse recovery What makes this test so compelling is its simplicity. Forget MRI scans or expensive ultrasounds, and forget relying on subjective gait assessments or enzyme tests. This is a world-first blood test. Non-invasive, stable, and gives trainers and vets something they've never had before: objective insight into how a horse is actually recovering. 'These exciting results mark a significant milestone in applying the OxiDx test to equine veterinary medicine,' said Proteomics' CEO, Dr Richard Lipscombe. 'OxiDx has the potential to empower trainers to monitor muscle recovery with precision, helping their racehorses achieve peak performance while prioritising equine health and well-being.' This is all about protecting high-value assets. After all, elite racehorses are routinely valued in the millions, and breeding stallions commanding even higher figures. OxiDx seems to have a first-mover foothold in this lucrative corner of the market. If all goes to plan, PIQ said the OxiDx test could be hitting Aussie stables by this time next year, potentially becoming a go-to tool for trainers. Animals are serious business While most of the world has its eye on human medicine, the animal health sector has been galloping ahead, quietly becoming one of the hottest areas in biotech. If you dig into the numbers, animal diagnostics is a actually billion-dollar market that's been growing faster than many areas of human healthcare. The market is driven by rising pet ownership and humanisation, growing demand for livestock productivity, and in this case, the high economic value of performance animals. It's serious business, especially when the animals in question are worth more than most houses. Other animal-relates stocks on the ASX Apiam Animal Health (ASX:AHX) Apiam is Australia's biggest rural and regional vet group, with boots on the ground from dairy farms to dog parks in over 70 locations nationwide. It's got 330-plus vets and a serious logistics backbone - warehouses in four states, national lab networks, and even eCommerce for livestock producers. And now, Apiam is rolling out CoVet, an AI-powered clinical tool that's already making traction in its network. Using voice recognition and smart templates, CoVet takes care of the boring stuff like generating notes and discharging instructions so vets can spend less time typing and more time treating. In June, Apiam appointed seasoned executive Bruce Dixon as interim managing director, following the departure of founding CEO Dr Chris Richards. Mad Paws (ASX:MPA) Mad Paws is Australia's go-to marketplace for pet care, connecting pet owners with trusted sitters, walkers, groomers, and a growing range of pet products and services. Launched in 2014, the company was built to solve the age-old question: 'What do I do with my pet when I'm away?' With 73% of Aussie households already owning pets, and spending over $3,000 per year on dogs alone, the market is big, sticky, and recession-resistant. And with consumer trends like pet humanisation on the rise, Mad Paws could be positioned to ride the wave. Aroa Biosurgery (ASX:ARX) While not directly in the pet or animal business, Aroa's use of ovine tissue put it in a unique position at the intersection of animal-derived innovation and human health. The New Zealand-born medtech company uses something pretty special to help the human body heal - tissue from the forestomach of sheep. Led by vet-turned-founder Dr Brian Ward, Aroa discovered that ovine tissue, particularly the extracellular matrix (ECM), closely mirrors human soft tissue and is packed with over 150 proteins vital to healing. After carefully stripping the tissue of cells and DNA, what's left is a natural scaffold that guides the body to regenerate itself, helping tissue repair in complex wounds. With FDA approvals, global distribution across 50+ countries, and standout clinical results, the company is hitting its stride. At Stockhead we tell it like it is. While Aroa Biosurgery is a Stockhead advertiser at the time of writing, it did not sponsor this article.